CONTRAST: Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation

Sponsor
Leiden University Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT05952583
Collaborator
Universitaire Ziekenhuizen KU Leuven (Other), Karolinska University Hospital (Other), BCNatal Fetal Medicine Research Center (Other), MOUNT SINAI HOSPITAL (Other), Boston Children's Hospital (Other)
274
5
60.4
54.8
0.9

Study Details

Study Description

Brief Summary

Optimal diagnostic management and underlying pathophysiological mechanisms of selective fetal growth restriction (sFGR) in monochorionic diamniotic (MCDA) twin pregnancies have not been fully clarified.

The current diagnostic classification system based on three different umbilical artery flow patterns has no increasing scale of severity and the predictive value is limited. Since there is no treatment available for sFGR, predicting fetal deterioration is key in preventing single or double fetal demise. Outcome prediction is furthermore important in the selection of cases that will be offered selective reduction (to provide the larger twin with better prospects), as well as determining monitor frequency and possible hospital admission. As outcome prediction is clinically challenging, patient counselling is too, and parents often encounter a great deal of uncertainty during the pregnancy.

Furthermore, little is known about the brain development of sFGR children (both during pregnancy and after birth). Moreover, the psychological impact of an sFGR pregnancy of the future parent)s) has not been studied before. The impact of these factors should be taken into account during patient counseling, which is currently not the case.

By our knowledge, this is the first international, multicenter, prospective cohort study on that will address the abovementioned questions and knowledge gaps in MCDA pregnancies complicated by selective fetal growth restriction.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Ultrasound

Detailed Description

Selective fetal growth restriction (sFGR) in monochorionic twins may negatively impact the pregnancy. There is a substantial risk of fetal deterioration resulting in (iatrogenic) preterm birth or even intrauterine demise of one, or both fetuses. There are important unresolved challenges on a diagnostic level and underlying pathophysiological mechanisms of sFGR have not been fully clarified.

The current diagnostic classification system based on three different umbilical artery flow patterns has no increasing scale of severity and the observed flow patterns may be volatile in nature. This hinders optimal diagnostic management and complicates outcome prediction as the survival outcome differs per umbilical artery flow type. Consequently, parents encounter a great deal of uncertainty during the pregnancy. Since there is no treatment available for sFGR, predicting fetal deterioration is key in preventing single or double demise.

By testing several predictors, we are aiming to improve outcome prediction at the time of sFGR diagnosis. We furthermore hypothesize that additional ultrasound parameters could be of benefit in making the current classification system more accurate and less variable. Extensive histological placental examinations will shine a light on microscopic abnormalities which can increase our knowledge of the pathophysiology. Examining neurodevelopment of sFGR twins at two years of age will additionally be of great value for our understanding of the impact of sFGR and contribute to adequate patient counselling. Our study will evaluate the impact of a sFGR pregnancy on parental mental health and parent-to-infant(s) attachment, which has not been carried out this extensively before.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
274 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation
Actual Study Start Date :
Feb 17, 2023
Anticipated Primary Completion Date :
Mar 1, 2025
Anticipated Study Completion Date :
Mar 1, 2028

Arms and Interventions

Arm Intervention/Treatment
sFGR cohort

Monochorionic diamniotic twin pregnancies complicated by sFGR (diagnosed before 28 weeks of gestational age)

Diagnostic Test: Ultrasound
Additional ultrasound measurements during pregnancy

Outcome Measures

Primary Outcome Measures

  1. Composite outcome [2 years]

    The composite outcome consists of fetal single or double demise, including selective fetal reduction and/or an iatrogenic elective birth < 32 weeks of gestational age because of fetal distress).

Secondary Outcome Measures

  1. Ultrasound parameters [2 years]

    Explanatory analysis of ultrasound parameters over course of sFGR pregnancy

  2. Prenatal and postnatal attachment [2 years]

  3. Post-traumatic stress [2 years]

  4. PARCA-R evaluation [2 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • MCDA twin pregnancy

  • Diagnosis of sFGR before 28+0 weeks of GA (independent of Doppler flows)

  • Pregnant woman ≥ 18 years and able to consent

  • Partner (who has (future) parental responsibility - if applicable) ≥ 18 years and able to consent

  • Written informed consent of both parents (if applicable) for participation in the longitudinal follow-up until 2 years after birth)

Exclusion Criteria:
  • The presence of lethal anomalies (one or both fetuses)

  • Multiple pregnancy higher order than twins;

  • TTTS/TAPS present at moment of sFGR diagnosis.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Universitaire Ziekenhuizen Leuven Leuven Belgium 3000
2 Mount Sinai Hospital Toronto Ontario Canada ON M5G 1X5
3 Leiden University Medical Center Leiden Zuid-Holland Netherlands 2333 ZA
4 BCNatal Barcelona Spain 08028
5 Karolinska University Hospital Stockholm Sweden 17164 Solna

Sponsors and Collaborators

  • Leiden University Medical Center
  • Universitaire Ziekenhuizen KU Leuven
  • Karolinska University Hospital
  • BCNatal Fetal Medicine Research Center
  • MOUNT SINAI HOSPITAL
  • Boston Children's Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
ejtverweij, Doctor, Leiden University Medical Center
ClinicalTrials.gov Identifier:
NCT05952583
Other Study ID Numbers:
  • CONTR
First Posted:
Jul 19, 2023
Last Update Posted:
Jul 19, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by ejtverweij, Doctor, Leiden University Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 19, 2023